Acciones Northwest Biotherapeutics, Inc Nasdaq
Acciones
US66737P6007
Biotecnología e investigación médica
Ventas 2022 | 1,68 M 1,55 M | Ventas 2023 | 1,93 M 1,78 M | Capitalización | 822 M 756 M |
---|---|---|---|---|---|
Resultado Neto 2022 | -105 M -96,57 M | Resultado Neto 2023 | -62 M -57,02 M | VE / Ventas 2022 | 505 x |
Deuda neta 2022 | 19,29 M 17,74 M | Deuda neta 2023 | 43,43 M 39,95 M | VE / Ventas 2023 | 448 x |
P/E ratio 2022 |
-7,59
x | P/E ratio 2023 |
-11,7
x | Empleados | - |
Rendimiento 2022 * |
-
| Rendimiento 2023 |
-
| Flotante | 90,82 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/01/00 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 01/04/12 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+8,89 % | 114 mil M | |
+11,47 % | 104 mil M | |
-12,63 % | 22,41 mil M | |
-1,05 % | 22,28 mil M | |
-5,29 % | 19,07 mil M | |
-38,29 % | 18 mil M | |
-3,08 % | 17,89 mil M | |
+7,86 % | 14,28 mil M | |
+35,95 % | 12,55 mil M |